Kenvue Inc.
https://www.jnj.com/kenvue
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kenvue Inc.
Talc Litigation Attorneys Allege ‘Bad Faith Filings,’ ‘Fraudulent Activities’ By J&J In Bankruptcy
Attorneys for some plaintiffs alleging harm from talc products J&J marketed ask a court to order the firm, along with a subsidiary holding company it created in 2021 to manage its talc liabilities and immediately placed in bankruptcy, to provide emails and other communications among in-house counsel and compel their testimony.
Supreme Court Decision Derailing Purdue Pharma Bankruptcy Could Trip J&J Talc Litigation Strategy
Supreme Court ruling on Purdue bankruptcy should “derail any attempt by J&J to return the talc litigation to the bankruptcy courts,” says class action plaintiff’s attorney. A federal court, Justice Gorsuch states, relieved Purdue owners of liability “without securing the consent of those affected or placing anything approaching their total assets on the table.”
Titans Of Pharma: J&J Back On Top For CEO Remuneration
J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.
Kenvue Makes Progress Transitioning From J&J Cash Stream To ‘Profitable Growth’ On Its Own
For Kenvue, 2023 “was really about separating from J&J” as a segment “mostly focused on profit and cash,” says CEO Thibaut Mongon. “But in 2024, you see a very different Kenvue in action.”
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice